Complete Hematologic Response and Cytogenetic Remission after Imatinib and Dexamethasone Treatment of a Ph+ Precursor B-cell Acute Lymphoblastic Leukemia in Renal Transplantation Patient.
- Author:
Sun Kyung BAEK
1
;
Kyung Sam CHO
;
Byung Hyuk YANG
;
Si Young KIM
;
Hwi Joong YOON
;
Kyunghwan JEONG
;
Chun Gyoo IHM
Author Information
- Publication Type:Case Report
- Keywords: Renal transplantation; Philadelphia chromosome; Acute lymphoblastic leukemia; Imatinib
- MeSH: Aged; B-Lymphocytes; Benzamides; Cerebral Hemorrhage; Cytogenetics; Dexamethasone; Humans; Kidney Transplantation; Philadelphia; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Pyrimidines; Imatinib Mesylate
- From:Korean Journal of Hematology 2009;44(1):62-66
- CountryRepublic of Korea
- Language:English
- Abstract: In this report, we present a case of a patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia after renal transplantation. The patient, a 65-year-old man, had received a kidney transplantation 20 years prior to diagnosis with Ph+ precursor B-cell ALL. Because he was refractory to intensive chemotherapy and had refused to receive additional intensive chemotherapy, he was treated with imatinib and dexamethasone. While this patient experienced a complete hematologic and cytogenetic response, he did not show a complete molecular remission. Eighty days after imatinib combination therapy, the patient relapsed and died from intracerebral hemorrhage.
